Medicamen Biotech Files BRSR Report for FY 2025-26

Medicamen Biotech Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, in compliance with SEBI regulations. The report details the company's corporate identity, operational activities, and financial performance. Key financial figures for FY 2025-26 include a paid-up capital of ₹13,56,28,150, total turnover of ₹178,84,58,167, and profit after taxes of ₹9,40,86,731. The company reported spending ₹25,20,000 on CSR activities, falling short of the statutory requirement by ₹6,13,024. Medicamen Biotech also disclosed its two subsidiaries, OPAL Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited, and confirmed that its Chairman, Rahul Bishnoi, is responsible for BR policy implementation.